A Korean health policy fight with global implications
In South Korea, one of the most closely watched health policy debates heading into March 2026 is not over a blockbuster cancer drug or a new pandemic measure. It is over whether the national health insurance system will broaden reimbursement for Evrysdi, an oral treatment for spinal muscular atrophy, or SMA, a rare genetic disease that causes progressive muscle weakness and can severely affect movement, swallowing and breathing.
To an American reader, that might sound like a narrow insurance decision involving one medicine in one country. In South Korea, it is being treated as something much bigger: a test of how far a modern national health system should go in covering ultra-expensive treatments for rare diseases, and how to do it in a way that is fair to patients while still financially sustainable.
The debate lands at a moment when Korea, like the United States and many other wealthy countries, is grappling with a new era in medicine. Scientific advances are producing treatments for conditions that once had few or no options. But those advances are often paired with staggering prices, complicated eligibility rules and uneven access depending on where patients live, how mobile they are, and how much support their families can provide. In other words, the science is moving faster than the systems meant to deliver it.
That is why Evrysdi has become such a powerful symbol in South Korea. The issue is not simply whether one more drug gets covered. It is whether Korea’s rare disease safety net can evolve from covering treatment in theory to making treatment workable in real life.
For families living with SMA, that distinction matters enormously. In rare disease care, the difference between “approved” and “accessible” can mean the difference between preserving function and losing it permanently.
What SMA is, and why timing matters so much
SMA is a hereditary neuromuscular disorder that damages the nerve cells responsible for controlling voluntary muscles. It affects infants, children and adults, though the severity can vary widely depending on the type of the disease and when symptoms begin. Some babies with the most severe forms face life-threatening complications very early. Others may walk in childhood and lose mobility over time. Adults can also live with progressive weakness that reshapes nearly every part of daily life.
For readers in the United States, SMA may be most familiar from fundraising campaigns around gene therapy or from broader conversations about rare diseases that suddenly entered public view because of social media, patient advocacy and high-profile drug approvals. But beyond those headlines, SMA is a condition in which timing is critical. The earlier treatment begins, the better the chance of preserving motor function. Once nerve damage progresses, recovery can be limited.
That urgency is a major reason health systems around the world have revisited coverage rules for SMA therapies. Delays are not just bureaucratic inconveniences. They can shape long-term medical outcomes. A patient who gets treatment months earlier may maintain abilities that another patient, facing insurance hurdles or geographic barriers, never regains.
South Korea has spent years strengthening coverage for severe and rare diseases through its single-payer National Health Insurance system. Americans can think of it as a universal framework that combines the reach of Medicare with a broader national mandate, though the structure and politics are different. Korea’s system has often been praised for achieving relatively efficient care and broad coverage. But rare disease drugs expose the stress points in any insurance model, public or private: Who qualifies? How much evidence is enough? How should value be measured when a disease affects relatively few people but carries enormous physical and emotional costs?
Those questions are especially sharp in SMA because treatment is not one-size-fits-all. Patients differ by age, disease progression, breathing support needs, prior treatment history and family caregiving circumstances. That makes reimbursement policy more than a spreadsheet exercise. It is also a clinical and ethical judgment about who can benefit, when and under what conditions.
Why Evrysdi stands out in a changing treatment landscape
The modern SMA treatment landscape is far different from what it was a decade ago. Care used to center largely on supportive measures: respiratory assistance, nutritional support, rehabilitation and efforts to manage complications. Today, there are therapies designed to target the biological mechanisms driving the disease.
Broadly speaking, the field now includes three well-known approaches: a treatment delivered into the spinal canal, a one-time gene therapy and an oral medication. Each comes with distinct trade-offs involving when it is used, how it is administered, how often patients must visit the hospital, what kind of monitoring is required, and how costs accumulate over time.
Evrysdi, known generically as risdiplam, has drawn particular attention because it can be taken orally at home. That may sound like a matter of convenience, but in rare disease care convenience can be the line between continuity and disruption. Families caring for medically fragile children often build their entire week around appointments, transportation and fatigue. Adults with severe mobility limitations may face grueling travel to tertiary hospitals, especially in a country where the biggest specialty centers are concentrated in and around Seoul.
In the United States, Americans often debate whether a drug is “worth it” based on sticker price, side effects and clinical benefit. In South Korea, the discussion includes those questions but also leans heavily on how a treatment fits into the national insurance framework and whether reimbursement rules reflect the realities of daily life. An oral option like Evrysdi can reduce the burden of repeated procedures and frequent hospital-based treatment. For caregivers, it can mean fewer missed workdays. For students and adults with SMA, it can mean less conflict between treatment schedules and school or employment.
None of that means Evrysdi is automatically the best option for every patient. Physicians generally do not view SMA therapies in simplistic winner-take-all terms. Instead, treatment decisions depend on clinical profile, age, disease stage, prior therapies and caregiving capacity. But broader reimbursement can make personalized treatment more than an abstract ideal. It can turn it into an actual choice.
That is one reason many Korean clinicians and patient advocates are treating the possible expansion as a milestone. They see it not merely as a commercial victory for one manufacturer, but as part of a broader shift in how rare disease medicine is judged: not only by whether a drug exists, but by whether patients can realistically stay on it over the long haul.
For families, the real issue is not just access but staying on treatment
Rare disease stories often focus on dramatic moments: a diagnosis, a regulatory approval, a breakthrough therapy. Less visible is the long middle of the story, the daily grind after the news cameras leave. That is where reimbursement rules matter most.
SMA is not a condition that begins and ends with a prescription. Families may spend years coordinating rehabilitation, breathing support, nutrition, infection prevention, home adaptations, school accommodations and emotional care. Parents can become quasi-case managers, navigating specialists, paperwork and schedules while trying to preserve some sense of ordinary life. Adult patients can face a different but equally taxing set of challenges, including work limitations, transportation barriers and the difficulty of finding providers who understand adult SMA, not just pediatric cases.
In that context, expanding reimbursement for a home-administered medicine has implications well beyond pharmacy costs. It can reduce what health policy experts sometimes call “friction costs” — the hidden burdens of receiving care, including travel time, missed wages, caregiver exhaustion and the logistical strain of repeated hospital visits.
Those burdens are especially pronounced outside the Seoul metropolitan area. South Korea is geographically smaller than the United States, but health care access still varies sharply by region. Major academic hospitals and rare disease expertise are concentrated in large urban centers. For patients living in provincial cities or rural areas, a hospital trip can consume an entire day and demand complicated transportation arrangements, especially for someone with severe physical limitations.
That means insurance expansion could improve not just nominal access but treatment continuity. And continuity matters because rare disease treatment often works best when it is steady, closely monitored and not repeatedly interrupted by cost or logistics. When families worry that treatment may become unaffordable or administratively uncertain, decisions get distorted. Appointments may be delayed. Therapy may be postponed. Psychological stress rises.
Broader reimbursement does not erase every one of those problems, but it can change the basic calculation. Families are less likely to ask first, “Can we afford to keep this going?” and more able to ask, “What is the best option medically?” In any health system, that is a meaningful shift.
Advocates also note that adult SMA patients have often received less policy attention than children, in Korea as in many countries. Pediatric rare diseases tend to attract greater public sympathy and political urgency, especially when early intervention is tied to developmental milestones. But adults with SMA also face progressive decline, high care needs and major barriers to sustained treatment. An oral drug with broader reimbursement could be particularly significant for that group, expanding real-world options in a population that has sometimes been overlooked.
The budget debate: How much should society pay for rare disease treatment?
Still, there is no way to separate the Evrysdi debate from money. SMA therapies are commonly categorized as high-cost medicines, and any move to expand coverage immediately raises questions about the long-term burden on the national insurance budget.
That tension will sound familiar to Americans, even if the systems differ. In the United States, disputes over expensive medicines often play out between drugmakers, insurers, pharmacy benefit managers, employers and government programs such as Medicaid and Medicare. In South Korea, where a national insurer has a more direct role, the debate is less fragmented but no less intense. The core issue is the same: resources are finite, and every decision to pay more in one category invites scrutiny over what else might be squeezed.
Korean policymakers must weigh rare disease coverage against a long list of competing demands, including cancer treatment, chronic disease care, essential medicines and the medical needs of a rapidly aging society. South Korea is aging faster than many Western countries, and that demographic shift is already putting pressure on health and long-term care spending. In that environment, expanding reimbursement for a rare disease drug can become politically sensitive even when the number of patients is relatively small.
Yet rare disease advocates argue, with reason, that simple cost-per-patient comparisons do not tell the full story. SMA is severe, often irreversible, and associated with immense caregiving burdens. Earlier and more reliable treatment may reduce hospitalizations, complications and other downstream costs. It may also preserve schooling, employment and family stability. Economists sometimes call those broader benefits “social value,” but for families they are less abstract: less time in the hospital, fewer emergencies, fewer career sacrifices by parents, more independence for patients.
This is why high-price rare disease drugs have become a proving ground for newer reimbursement tools in many countries, including risk-sharing agreements, outcomes-based payments and post-market data collection. The idea is to move beyond an all-or-nothing model in which a government either accepts a sky-high price or denies coverage outright. Instead, payers try to link payment to real-world performance, negotiate rebates or spread risk over time.
South Korea has been exploring versions of those approaches, and the Evrysdi case is likely to intensify calls for more sophisticated payment models. If Korean authorities expand coverage, they will still need to justify the decision to taxpayers and to other patient groups. If they do not, they will face criticism that medical innovation is being rationed too tightly. Either way, the case exposes the balancing act at the heart of modern universal health care.
The fairness question may be even harder than the price question
Cost is only one side of the policy argument. Fairness may be even more difficult.
When a government broadens reimbursement, the headline usually sounds straightforward: coverage has expanded. But in practice, eligibility criteria determine who actually benefits. Patients may be included or excluded based on age, disease type, current motor function, prior treatment experience or whether they use respiratory support. Those rules can create sharp distinctions within the same disease community.
That is one reason Korean patient groups have closely watched not just whether reimbursement expands, but how. A broad policy on paper can still leave meaningful gaps if the criteria are too strict. A patient who technically falls outside one line of eligibility may experience the decision as arbitrary, especially in a disease where progression is continuous and every month matters.
This problem is not unique to Korea. American families dealing with rare diseases are familiar with similar frustrations, whether involving private insurance denials, prior authorization hurdles or state-by-state Medicaid variation. But the Korean case shows how these dilemmas look inside a universal system. Universal coverage does not automatically eliminate exclusion. It often relocates it into the fine print.
That is why experts say the central question is not merely whether Korea covers rare disease treatment, but how far public responsibility should extend in supporting the full life course of patients. Does coverage stop at the drug itself? Or should it be linked to rehabilitation, genetic counseling, regular functional evaluation, mental health support and regional care infrastructure? A medicine can be reimbursed and still fail to deliver its full benefit if the surrounding system is weak.
For SMA patients, integrated care matters. Drug access is only one part of the equation. Delayed diagnosis, uneven regional expertise, shortages in rehabilitation services and limited long-term adult care all shape outcomes. If reimbursement expands without addressing those structural issues, the policy may help, but not as much as families hope.
A turning point for Korea’s rare disease model
That is what makes the Evrysdi decision so significant. It sits at the intersection of medical innovation, family life, public finance and social values. South Korea is not just deciding whether to pay for more of one SMA treatment. It is sketching the outline of what its next-generation rare disease model might look like.
The country has already shown a willingness to expand protection for severe illnesses. But the arrival of gene therapies, cell therapies and other ultra-expensive specialty drugs is forcing a more complicated conversation. Coverage can no longer be judged only by whether a medicine is added to a reimbursement list. Policymakers now have to consider administration burden, continuity of care, regional access, long-term evidence and the lived experience of patients and caregivers.
In that sense, the debate over Evrysdi resembles broader debates unfolding across affluent democracies. How should societies distribute the benefits of biomedical innovation? How much uncertainty are public payers willing to accept when evidence is still evolving? And how can systems protect patients with rare conditions without undermining the fiscal trust that universal programs depend on?
South Korea does not have all the answers, and neither does the United States. But the Korean case is worth watching because it highlights a truth that applies far beyond one country or one disease: the hardest part of modern medicine is often not inventing a treatment. It is building a fair way to deliver it.
If Korea moves forward with broader reimbursement for Evrysdi, the immediate impact could be tangible for families who need a more manageable treatment option. Over time, the bigger effect may be precedent. Future debates over rare disease drugs will likely cite this decision, whether as a model of balanced expansion or as a warning about the limits of insurance generosity.
Either way, the stakes reach beyond SMA. They touch on a core promise of advanced health systems: that patients facing devastating but uncommon illnesses will not be left behind simply because their numbers are small and their treatments are expensive. Whether South Korea can keep that promise, and on what terms, is what makes this one reimbursement fight matter so much.
0 Comments